Loading…
← CockpitCompetitor Analysis › PRME Prime Medicine, Inc.Open in the cockpit ↗

Prime Medicine, Inc.PRMECompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 88
Mkt cap
$695M
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$27.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 14.4%
Hurdle
n/a
no reverse DCF
Next earnings
112 days
10 Mar 2027
Close · USD$3.82
1D-0.5%
1W-11.2%
1M-2.5%
3M+17.9%
6M+35.0%
YTD+10.1%
1Y0.0%
ATR %12.6%
Beta2.46
52w lowhigh35.4% off high

What Prime Medicine does

Employees: 146

Prime Medicine at a glance

Size Prime Medicine (PRME) is a United States Health Care company (Biotechnology) with a market value of $695M, the 2463rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.82 on 18 Nov 2026.

Performance Over six months the shares gained 35.0%, against -23.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue grew 18.1% over the last twelve months (peer median +13.3%); the operating margin is -2,584.2% (peer median -76.8%).

Valuation It trades at 105.4× enterprise value to sales against a peer median of 6.9× (3rd most expensive of 16).

Short interest Short interest is 16.1% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026PRME 129Peer median 76
Six months, rebased to 100: Prime Medicine against the median of its 20 peers (local-currency closes).

Prime Medicine financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$7.06M$4.63M$2.98M$0$0
Revenue growth—+55%———
Gross profit-$215,000-$2.69M-$3.15M-$4.65M-$12.0M
EBITDA-$175M-$201M-$196M-$187M-$105M
Net income-$176M-$201M-$196M-$198M-$122M
Free cash flow-$159M-$167M-$130M-$174M-$148M
Capital expenditure$848,000$4.53M$7.29M$8.72M$16.1M
Total debt$110M$116M$40.8M$13.6M$28.7M

Quarterly statements and history in the cockpit →

Prime Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%301520SLDBATTOKURA30133377299966688221AURAGERN9887JANXPRME6-month return →1-month return →
Up and to the right = strong over both horizons. Prime Medicine is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%0×5,000×10,000×301520KURA688197IVAPRMERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Prime Medicine is the large dot.

Prime Medicine competitors and peer comparison

How Prime Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Prime Medicine against its 20 peers (data as of 18 Nov 2026)
MeasurePRMEPeer medianRank in peer set
1-month return-2.5%-7.3%7th highest of 21
6-month return+35.0%-23.5%4th highest of 19
Distance from 52-week high-35.4%-47.7%5th highest of 21
Revenue growth (TTM)+18.1%+13.3%8th highest of 15
Operating margin-2,584.2%-76.8%3rd lowest of 17
EV / Sales105.4×6.9×3rd most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%

Questions

Which companies are Prime Medicine's closest peers?
The cockpit's peer set: Anhui Wanbang Pharmaceutical Technology (301520.SZ), Solid Biosciences (SLDB), Attovia Therapeutics (ATTO), Shaanxi Micot Pharmaceutical Technology (2335.HK), Kura Oncology (KURA), R&G PharmaStudies (301333.SZ), Steminent Biotherapeutics (7729.TWO), Alphamab Oncology (9966.HK).
Is Prime Medicine expensive compared with its peers?
On ev / sales it trades at 105.4× against a peer median of 6.9×, 3rd most expensive of 16 in its peer set.
How has Prime Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned +35.0% against -23.5% for the median peer; over one year 0.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.